CTLA4 and neoplasm: Furthermore, preclinical data has indicated that CTLA-4-blockade has a significant effect on boosting the anti-tumor response, suggesting that targeting CTLA-4 could serve as a viable method for activating cytotoxic T-lymphocytes (CTLs) in cancer therapy (66–68).